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ABSTRACT
Nitrosative stress has been implicated in the pathogenesis of age related 
macular degeneration (AMD). Tyrosine nitration is a unique type of post translational 
modification that occurs in the setting of inflammation and nitrosative stress. To 
date, the significance and functional implications of tyrosine nitration of complement 
factor H (CFH), a key complement regulator in the eye has not been explored, and is 
examined in this study in the context of AMD pathogenesis.
Sections of eyes from deceased individuals with AMD (n = 5) demonstrated 
the presence of immunoreactive nitrotyrosine CFH. We purified nitrated CFH from 
retinae from 2 AMD patients. Mass spectrometry of CFH isolated from AMD eyes 
revealed nitrated residues in domains critical for binding to heparan sulphate 
glycosaminoglycans (GAGs), lipid peroxidation by-products and complement (C) 3b.
Functional studies revealed that nitrated CFH did not bind to lipid peroxidation 
products, nor to the GAG of perlecan nor to C3b. There was loss of cofactor activity 
for Factor I mediated cleavage of C3b with nitrated CFH compared to non-nitrated 
CFH. CFH inhibits, but nitrated CFH significantly potentiates, the secretion of the pro-
inflammatory and angiogenic cytokine IL-8 from monocytes that have been stimulated 
with lipid peroxidation by-products. AMD patients (n = 30) and controls (n = 30) 
were used to measure plasma nitrated CFH using a novel ELISA. AMD patients had 
significantly elevated nitrated CFH levels compared to controls (p = 0.0117). These 
findings strongly suggest that nitrated CFH contributes to AMD progression, and is a 
target for therapeutic intervention.
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INTRODUCTION
Age-related macular degeneration (AMD) is a 
leading cause of irreversible vision loss in people aged 
over 50 years in developed countries [1].
Multiple lines of evidence suggest that dysregulation 
of the alternate complement system is an important 
contributor to AMD pathogenesis [2]. Furthermore, 30-
50% of genetic susceptibility to AMD is conferred most 
strongly by the complement factor H (CFH) Y402H 
polymorphism, resulting in a tyrosine(Y)-to-histidine(H) 
substitution at amino acid position 402 within the CFH 
protein [3–6]. CFH is a major negative regulator of 
the alternate complement pathway [7]. The alternate 
complement system is triggered when C3 is converted to 
C3b. C3b forms the C3 convertase complex that through 
a positive feedback loop amplifies C3b generation, which 
then goes on to form part of the C5 convertase complex, 
ultimately leading to the formation of the complement 
membrane attack complex. C3b is promiscuous in 
its ability to opsonize not only pathogen surfaces but 
also healthy cell surfaces, and the latter can lead to co-
lateral damage of the host cells unless C3b is promptly 
inactivated by regulatory proteins such as CFH at these 
sites [7].
CFH is an abundant plasma protein that is composed 
of 20 complement control protein modules or domains. 
CFH promotes Factor I mediated C3b inactivation by 
binding C3b predominantly through domains 1-4 at the 
N-terminus of the CFH molecule [8]. CFH can provide 
Factor I cofactor activity to inactivate C3b either in the 
plasma fluid phase or on the surface of cells [8]. CFH 
can also localize to Bruch’s membrane (BM) (a semi-
permeable structure that separates the choroidal blood 
supply from the retina) by binding to glycosaminoglycans 
(GAGs) such as heparan sulphate [9], a major type being 
perlecan [10]. CFH domains 6-8 and 19-20 have been 
shown to play an important role in heparan sulphate 
binding, resulting in a conformation that allows domains 
1-4 of CFH to then interact with C3b [8]. Domains 
7 and 20 have also been shown to be important in 
facilitating CFH binding to malondialdehyde (MDA) and 
malondialdehyde acetaldehyde (MAA) which are lipid 
peroxidation byproducts detected in drusen deposits in 
AMD eyes [11]. CFH binding to MDA/MAA inhibits 
amplification of the alternate complement system by 
promoting C3b cleavage to inactive iC3b fragments [11]. 
Of note the Y402H variant of CFH displays significantly 
diminished binding to heparan sulphate [9] and to MDA/
MAA modified molecules, and concurrent loss in its 
ability to inactivate C3b [11]. This provides a mechanistic 
account of how this polymorphism leads to dysregulation 
of the alternate complement system in AMD.
Tyrosine nitration is a type of oxidative post-
translational modification of proteins that occurs as a 
downstream consequence of peroxynitrite mediated 
attachment of a NO2 moiety to a tyrosine residue within 
the protein [12]. Peroxynitrite is generated in the setting 
of excess levels of reactive oxygen species in the presence 
of nitric oxide or nitric oxide derived metabolites (also 
termed nitrosative stress) [12]. Tyrosine nitration has 
been shown to affect extracellular proteins in BM, and the 
degree of nitration increases with age [13]. The possible 
relevance of tyrosine nitration to the pathophysiology of 
the ageing process has previously been emphasized [14]. 
Whether tyrosine nitration of complement regulatory 
proteins such as CFH occurs, and if so what are the 
functional implications of this, has not been explored to 
date, and is the aim of this study in the context of AMD 
pathogenesis.
RESULTS
Co-localization of CFH and nitrotyrosine 
immunoreactivity in the choroid and retina of 
AMD eyes
Paraffin sections of AMD eyes (n = 5, age of patients 
69, 78, 83, 84 and 93 with Grade 1 to 4 Age-Related Eye 
Disease Study (AREDS) staging were examined for 
expression of CFH and nitrotyrosine using single and double 
immunolabelling and confocal microscopy. A monoclonal 
antibody that specifically binds to 3-nitrotyrosine was used 
to detect the latter. We observed areas of colocalisation 
of CFH and 3-nitrotyrosine immunoreactivity in the 
extracellular matrix (ECM) surrounding the choriocapillaris, 
including the choriocapillaris pillars in all specimens; 
evidence of colocalization also was observed in BM in some 
specimens. Representative examples from two patients with 
AMD are shown in Figure 1a (1-4) is from an 83 year old 
female AREDS Grade 1 and b-e is from a 93 year old female 
AREDS Grade 4.
Characterization of a specific monoclonal 
antibody to nCFH
On Western blotting the monoclonal anti-
nitrotyrosine specific antibody (C166) bound to CFH 
that was tyrosine nitrated in vitro (using the method of 
heme dependent nitration) [15], but not to nitrated (n)BSA 
prepared in an identical manner. Furthermore, it did not 
bind non-nitrated CFH (Figure 2), confirming its restricted 
specificity for nitrated (n)CFH on Western blotting.
Identification of nCFH in retinal extract from 2 
deceased patients with early and late AMD
One unfixed donor eye (83 year old female AREDS 
Grade 1, cause of death an intracerebral haemorrhage) 
with evidence of macula drusen was dissected and the 
retina including the choroid gently removed and snap 
frozen in liquid nitrogen and extracted as indicated in 
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Figure 1: a. Immuno-localisation of CFH and nitrotyrosine in the choroid and retina in an early AMD human eye (1-4). (1) Nuclei are 
counterstained with bisbenzimide (blue). (2) Double immunolabelling for CFH (green) and (3) nitrotyrosine (NTyr) (red) in the retina and 
choroid from an eye with early AMD (83 year old, female, AREDS Grade 1). Image in 4 is merged and shows colocalisation (yellow) 
of CFH and NTyr in Drusen (*), RPE, Bruch’s membrane and extracellular matrix around the choriocapillaris (Ch). Arrows indicate 
site of colocalisation. b. Right (RE) and left (LE) postmortem eyes (93 yo, dry AMD AREDS grade 4) photographs showing areas of 
atrophy in the macular region of each eye (arrow – fovea). Representative image of a haematoxylin & eosin stained paraffin section of 
the retina and choroid from the RE dry AMD lesion, showing disrupted retinal pigment epithelium (RPE) and sub-RPE deposits. Note the 
thinned outer nuclear layer and remnants of photoreceptor outer segments (arrows) (GCL: ganglion cell layer; INL: inner nuclear layer). c. 
Immuno-localisation of CFH and nitrotyrosine in the choroid and retina in the human eye shown in b. (1) Nuclei are counterstained with 
bisbenzimide (blue). (2) Immunostaining for CFH (green) and (3) NTyr (red). (4) Colocalisation of CFH and NTyr are seen in the BrM 
(arrows point to area of colocalisation). Small areas of CFH and NTyr co-localisation (merge, *) are seen in the extracellular matrix around 
the choriocapillaris (cc). Remnants of RPE are visible (**) in this area, and the outer nuclear layer is not visible, associated with outer retinal 
atrophy. d. Immunolabelling with immunoglobulin (Ig) control (1) Nuclei are counterstained with bisbenzimide (blue). (2) Rabbit (RIg) 
(green) and (3) goat (GIg) (red) shows some non-specific immunolabelling (cc: choroiocapillaris; INL: inner nuclear layer; BrM: Bruch’s 
membrane). e. High power image of Figure 1c (4) demonstrating immuno-localisation of CFH (green) and nitrotyrosine (red) in the Bruch’s 
membrane (BrM) / choroiocapillaris region of the dry AMD human eye. Nuclei are counterstained with bisbenzimide (blue). Small areas 
of CFH and NTyr co-localisation (merge, *) are seen in the extracellular matrix around the choriocapillaris (cc) and in cell remnants just 
above Bruch’s membrane (arrows).
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methods. Figure 3a shows total protein extract (lane 1). 
Affinity purified material was isolated from the total 
protein extract derived from the retina (lane 2). The total 
protein extract was subjected to affinity purification with 
the specific monoclonal antibody derived against Ac-
KEKKCS (YNO2) TED-NH2 peptide sequence from 
Apolipoprotein H (designated C166). The total protein 
extract and eluate were subjected to Western blotting 
with the anti-nitrotyrosine CFH monoclonal antibody 
C166 (Figure 3a, lanes 1 and 2 respectively) to confirm 
that the affinity purification isolated nCFH. Only two 
immunoreactive bands were identified (lanes 1 and 2) 
which migrated with identical molecular weights to those 
observed with immunostaining on Western blot with the 
C166 monoclonal antibody of native CFH nitrated in vitro 
(Figure 2, lane 2). The affinity purified retinal sample 
was also probed with a different antibody that binds to 
non-nitrated CFH demonstrating immunoreactivity at 
molecular weights identical to those detected with the 
C166 monoclonal antibody (Figure 3, lane 3). The affinity 
purified retinal extract was subjected to SDS-PAGE and 
stained with silver which demonstrated two faint bands 
(Figure 3b) at the identical molecular weight to those 
identified on Western Blotting of the total protein and 
affinity purified extracts (Figure 3a).
A second donor eye (93 year old female AREDS 
Grade 4, cause of death a myocardial infarction) with 
end stage dry AMD was dissected and the retina carefully 
separated from the choroid. The macula was removed 
using an 8 mm trephine and isolated from the rest of 
the retina, with further separation of the choroid/retinal 
pigment epithelium (RPE). The individual samples 
were extracted and processed as indicated in methods. 
The extracts from the various locations of the eye were 
subjected to Western blotting with the monoclonal anti-
nCFH antibody C166. The immunostaining demonstrated 
bands at MW of ~170kDa and >170 kDa in the macula 
retina (Figure 3c, lane 2). There was faint staining of the 
same MW bands in the retina without the macula (Figure 
3c, lane 1) and the choroid/RPE from below the macula 
Figure 2: Western blot of CFH and BSA preparations probed with the specific anti-nCFH monoclonal antibody. A 
major immunoreactive band migrating at ~ 170 kDa and a minor band migrating at >300 kDa (lane 2) was observed with purified CFH that 
was nitrated in-vitro. There was no immunoreactive band detected with CFH (lane 1) and nBSA (lane 3).
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(Figure 3c, lane 3). There was no staining detected in the 
choroid/RPE from below the non-macular retina (Figure 
3c, lane 4).
Arrows indicate molecular weight of nCFH reactive 
bands.
Mass spectrometry identified the CFH tyrosine 
residues that are nitrated in AMD retina
The two silver stained bands indicated by the arrows 
in Figure 3b were excised and subjected to tandem mass 
spectrometry to identify the nitrated residues and the 
specific proteolytic peptides in which they occur.
The mass spectrometry analysis identified CFH as 
the only protein contained within these 2 bands (with the 
exception of contaminant proteins including trypsin and 
keratin), confirming the specificity of the antibody C166 
for nitrated CFH. The two immunoreactive bands migrate 
at a higher molecular weight than non nitrated CFH which 
could be due to nitration and/or multimer formation. The 
CFH tyrosine residues that are nitrated in the retina of a 
deceased individual with AMD, are summarized in Table 
1. For peptides containing multiple tyrosine residues, the 
site of nitration was determined based on the theoretical 
nitrated peptide tandem mass spectrum with highest ion 
score as determined by Mascot. An example tandem mass 
spectrum showing the detection of NO2Y1177 in domain 
20 of CFH is shown in Figure 3d. Overall, 35% coverage 
of the CFH derived from the retina was achieved by the 
mass spectrometry analysis. There was no coverage of the 
Figure 3: Purification of nCFH from the retina of a deceased individual with AMD (83 year old, female, AREDS 
Grade 1). a. Lane 1 demonstrates a Western blot of whole protein extract from the AMD retina probed with the C166 antibody. Lane 2 
affinity purified sample obtained by applying the whole protein extract from the AMD retina to an anti-nCFH monoclonal antibody affinity 
column probed with the C166 antibody. Lane 3, the affinity purified sample probed with a specific antibody to CFH. b. Silver stain of the 
affinity purified AMD retinal extract. The two arrows indicate the bands that were excised and subjected to tandem mass spectrometry to 
identify the nitrated residues. c. Western blot of whole protein extract from distinct regions of the retina from a patient with AMD (93 year 
old, female, AREDS Grade 4) probed with the C166 monoclonal antibody.1 = retina without macula, 2 = macula retina (8 mm trephine), 3 
= choroid/RPE from below macula (8 mm trephine), 4 = choroid/RPE from rest of eye. d. An example tandem mass spectrum showing the 
detection of NO2Y1177 (Domain 20), from the affinity purified sample (b).
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tyrosines in Domain 7 nor for some of the other domains 
(Figure 4). The amount of CFH protein available for in 
vitro nitration and subsequent analysis was significantly 
higher than the in vivo samples which required multiple 
purification steps which included homogenisation, lysis, 
acetone precipitation to remove detergent and affinity 
purification with the C166 monoclonal antibody affinity 
column. This means there is significant loss of protein at 
each step and hence the amount of nCFH for analysis was 
simply limited for mass spectrometry detection.
Tyrosine residues of CFH that were nitrated 
in vitro
In order to perform in vitro functional experiments 
using nCFH, CFH was nitrated in vitro using the method 
of heme-dependent nitration [15] and we confirmed 
the nitration of specific tyrosine residues using mass 
spectrometry as described above. Overall 59% coverage 
of the CFH nitrated in vitro was achieved by the mass 
spectrometry analysis (Figure 4). Table 1 summarises the 
nitrated residues (>10% nitration, quantified by relative 
ion intensity of nitrated peptide versus the unmodified 
peptide) and their domain location in the in vivo and in 
vitro derived CFH.
CFH but not nCFH binds MDA-LDL and MAA-
BSA
We were interested to know whether nitration of 
CFH modified its binding to MDA or MAA modified 
proteins and lipoproteins. Figure 5a demonstrates the 
degree of binding of MDA-low density lipoprotein (LDL) 
to CFH, nCFH, CFH plus NaNO2 or CFH plus H2O2. 
There was specific binding to CFH and the CFH controls 
treated with NaNO2 or H2O2 but only background binding 
to nCFH. Figure 5b demonstrates the degree of binding of 
biotinylated MAA-BSA to CFH, nCFH (with the nitrating 
mixture) or purified nCFH (nitrating mixture removed). 
There was specific binding to CFH but only background 
binding to nCFH or purified nCFH. There was no binding 
of biotinylated BSA to CFH (<0.1), nCFH (<0.1) or 
purified nCFH (<0.1) at OD = 370 nm.
CFH but not nCFH binds the heparan sulphate 
perlecan
Binding of CFH to immobilized perlecan was 
assessed by ELISA with bound CFH being detected by 
an anti-CFH antibody. Significant amounts of both CFH 
and nCFH bound to the basement membrane heparan 
sulphate proteoglycan, perlecan when compared to control 
wells. Interestingly, the amount of binding of nCFH 
compared to CFH was significantly reduced suggesting 
that the nitration modification of some of the tyrosines is 
important in the binding (Figure 6). The control contained 
the nitration mixture alone.
CFH but not nCFH binds to C3b
CFH bound to immobilised C3b (mean OD = 1.3). 
In contrast nCFH had significantly less binding (mean 
OD = 0.31, n = 3, p = 0.024). Treatment of CFH with 
the nitration mixture controls Cytochrome C (mean 
Table 1: Summary of all CFH nitrated peptides detected by tandem mass spectrometry
Peptide Nitrated residue CFH domain In vivo In vitro
CNMGYEYSER 241, 243 4 x x
SCDNPYIPNGDYSPLR 271 5 x
NGFYPATR 299 5 x
CTLKPCDYPDIK 327 6 x x
HGGLYHENM(+16)R 336 6 x
RPYFPVAVGK 344 6 x x
SIDVACHPGYALPK 420 7 x
LGYVTADGETSGSITCGK 481 8 x
SSQESYAHGTK 891 15 x
AGEQVTYTCATYYK 1021 17 x x
DTSCVNPPTVQNAYIVSR 1058 18 x x
EIMENYNIALR 1177 20 x x
A nitrated peptide is marked as detected if it was identified by the Mascot algorithm. Location of the nitrated tyrosine is 
determined based on the theoretical nitrated peptide tandem mass spectrum with the highest Mascot score. The CFH domain 
is based on the protein annotation from the UniProt database. Tyrosines included were detected at greater than 10% nitration. 
The Y in bold denotes the nitrated tyrosines.
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OD = 1.2), H2O2 (mean OD = 1.1) or NaNO2 (mean OD = 
1.2) did not affect binding at OD = 405 nm.
CFH mediates cleavage of C3b, which is 
abolished upon nitration of CFH
CFH provided cofactor activity for Factor I to 
cleave C3b with an immunoreactive band migrating at 
approximately 43 kDa, Figure 7, lane 2 indicated by the 
arrow. However, nitration of CFH abolished the cofactor 
activity of CFH for cleavage of C3b by factor I (Figure 7, 
lane 3).
CFH inhibits, but nCFH significantly potentiates 
IL-8 release from MAA-BSA stimulated human 
monocytes
CFH but not the nitrated form neutralised the 
pro-inflammatory effects of MAA-BSA. It has been 
proposed that the secretion of cytokines, including IL-8, 
are responsible for the inflammation associated with the 
pathogenesis of AMD [16]. We were interested to see 
whether the nitrated form of CFH had any effect on IL-8 
production induced by MAA-BSA. MAA-BSA increased 
IL-8 secretion in THP-1 monocytic cells compared to 
medium alone, which was significantly inhibited in the 
presence of CFH (Figure 8). In contrast incubation of 
THP-1 cells with nCFH induced secretion of IL-8 equal to 
that of MAA-BSA alone and significantly increased IL-8 
secretion when compared to CFH alone (p = 0.03) (Figure 
8). In the presence of nCFH, MAA-BSA dramatically 
increased the secretion of IL-8 up to 11-fold compared to 
MAA-BSA alone, nCFH alone or MAA-BSA plus CFH. 
The control consisted of H2O2 with CFH (Figure 8).
Plasma levels of nCFH are increased in AMD 
patients compared to controls 
We developed a novel ELISA method for detecting 
nCFH levels in plasma and compared levels of nCFH in 
plasma samples from a cross section of AMD patients and 
controls. AMD patients had statistically significant higher 
plasma levels of nCFH (4.22 ng/ml ± 8.61, mean ± SD, n 
= 30) compared to controls  (1.73 ng/ml ± 2.97, mean ± 
SD, n = 30) (p = 0.0109) (see patient and control details 
in the methods). 
DISCUSSION
In this study we have made the major findings that 
CFH can exist in a nitrated form in vivo, and that nCFH 
can be detected in retina/choroid of patients with AMD 
with increased levels in their plasma compared to controls. 
Mass spectrometry analysis of CFH isolated from an AMD 
affected retina, using a novel monoclonal antibody that 
has restricted specificity to CFH nitrotyrosine residues, 
demonstrated that a number of CFH tyrosine residues 
that are nitrated in the AMD retina are contained in 
domains 4, 6 and 20 that serve important functional roles. 
CFH domain 4 (along with domains 1-3) contributes to 
binding C3b, providing cofactor activity for Factor I [8]. 
CFH domains 6 and 20 (along with domains 7/8 and 19) 
contribute to binding to heparan sulphated GAGs [8], and 
also permit colocalization of CFH to cell surfaces and 
onto lipid peroxidation modified debris such as MDA/
MAA residues [11]. This allows CFH to limit destructive 
amplification of the alternate complement system at 
Figure 4: Summary of all CFH nitrated peptides detected in vitro and in vivo by tandem mass spectrometry. Sequence 
coverage of peptides is shown in different colours.
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these sites. We show that the novel nitrotyrosine post-
translational modifications we have identified both in 
vitro and in vivo in these critical domains impair CFH 
function in ways that would be expected to amplify the 
pathogenesis of AMD as discussed below.
Lipid peroxidation byproducts such as MDA/
MAA, have been detected in AMD eye samples and can 
potentiate the activation of the alternate complement 
system, and elicit a pro-inflammatory cytokine response 
[11]. IL-8 may also promote new vessel formation [17]. 
CFH can bind to MDA/MAA residues through domains 
7 and/or 20 and limit the activation and amplification 
of the alternate complement pathway by inactivating 
C3b to iC3b, and furthermore CFH inhibited MDA/
MAA triggered pro-inflammatory cytokine release [11]. 
Domain deletion mutants of CFH that did not contain 
either domain 7 or 20 lost approximately 50% of their 
binding capacity to MDA/MAA [11] respectively. In our 
study we demonstrate that nitration of tyrosine residues 
of CFH (Domains 4 and 20) known to play key roles in 
binding to complement components and MDA/MAA 
respectively lose the ability to inactivate C3b to iC3b and 
to bind MDA/MAA residues. Furthermore, rather than 
merely losing the ability to inhibit MDA/MAA mediated 
activation of monocytes, nCFH significantly potentiates 
this proinflammatory effect, suggesting it can amplify the 
deleterious effects of inflammation in the retina of AMD 
patients. Cytokines such as IL-8 have been proposed as 
being relevant in driving AMD lesions [16, 18].
Not all individuals who have the CFHY402H 
polymorphism develop AMD which suggests that 
there may be environmental factors that through post-
translational modifications further disrupts CFH 
function, thus allowing AMD to develop. We propose 
that nitrosative stress may promote AMD progression in 
individuals who carry the CFHY402H polymorphism by 
post-translationally modifying the key tyrosine residues 
of CFH we have identified in the functional domains 4, 
Figure 5: a. Binding of MDA-LDL to CFH preparations – binding of MDA-LDL to CFH, nCFH, CFH plus NaNO2 or CFH plus H2O2 was 
assessed by ELISA. Bound MDA-LDL was detected using a specific anti-MDA antibody. There was significant binding to CFH, CFH plus 
NaNO2 or H2O2 but not to nCFH. b. Binding of biotinylated MAA-BSA to CFH preparations – binding of biotinylated MAA-BSA to CFH, 
nCFH or purified nCFH was assessed by ELISA. Bound biotinylated MAA-BSA was detected using streptavidin HRP. NO2-CFH = nCFH.
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Figure 7: CFH but not nCFH cleaves C3b - Cleavage of C3b by CFH and nCFH was assessed using Western blot. C3b 
was incubated with Factor I and CFH or nCFH and assayed for degradation products. In the presence of CFH, C3b was cleaved by Factor I 
to a fragment with a mobility at approximately 43 kDa detected with an anti-C3 antiserum (lane 2) whereas in the presence of nCFH, C3b 
was not degraded by Factor I (lane 3). Arrow indicates degradation product.
Figure 6: Binding of CFH to immobilized perlecan was assessed by ELISA. Bound CFH was detected by an anti-CFH 
antibody. There was significant binding to perlecan by CFH but not nCFH. The control contained the nitration mixture alone. 
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Figure 8: CFH inhibits whereas nCFH potentiates IL-8 secretion from human monocytes stimulated by MAA-BSA. 
IL-8 was secreted by THP-1 cells following stimulation for 18 h with MAA-BSA. The effect of different combinations of CFH and nCFH on 
IL-8 secretion by THP-1 cells are shown. CFH: complement factor H; nCFH: nitrated CFH; MAA: MAA-BSA; H2O2: hydrogen peroxide.
Figure 9: Standard curve for nCFH. Purified nCFH at different concentrations was added to CFH deficient plasma to construct the 
standard curve as described in methods.
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6 and 20. The other nitrotyrosine modified CFH residues 
in domains 15, 17 and 18 we have identified in CFH from 
AMD retina may also contribute to impairing optimal 
CFH function and this warrants further investigation.
An important GAG contained in the BM is heparan 
sulphate [9], which decorates the protein core of heparan 
sulphate proteoglycans including perlecan, agrin and 
type XVIII collagen. CFH domains 6-8 and 19-20 play 
an important role in allowing CFH to bind to heparan 
sulphate [8], allowing it to localize within BM [19], thus 
permitting inactivation of C3b in this location. Elderly 
individuals have been noted to display decreased levels 
of sulphation in BM [9]. In our study we sought to 
assess whether tyrosine nitration of native CFH affected 
its ability to bind perlecan. Nitrated CFH demonstrated 
significantly lower binding to perlecan compared to non 
nCFH, suggesting that tyrosine nitration of CFH in vivo is 
likely to significantly inhibit its ability to bind and localize 
to perlecan within BM and hence limit its capacity to 
provide sufficient Factor I cofactor activity to inactivate 
C3b at this location. This may have further implications 
for AMD pathogenesis as it has been shown that the 
physiological concentration of CFH competitively inhibits 
lipoproteins from binding to heparan sulphate residues in 
the BM hence limiting lipid deposition at this site [20]. 
Dysregulated lipid deposition has been suggested to be an 
important contributor to AMD pathogenesis by Curcio and 
colleagues [21]. Hence we postulate that tyrosine nitration 
of CFH in vivo may potentiate inappropriate lipoprotein 
build up in BM due to the loss of ability of nCFH to bind 
heparan sulphate as effectively as non nCFH, leading to 
loss of ability to competitively inhibit lipoprotein binding 
to BM.
In this study we were able to demonstrate that 
quantitation of nCFH in the plasma is feasible, and that 
elevated levels of nCFH are significantly higher in a 
cohort of AMD patients compared to controls. This raises 
the possibility that quantitation of nCFH in plasma may 
allow for risk stratification in individuals with early AMD, 
and is an area of research that can be pursued with future 
well designed, large prospective studies. It will be useful 
to know whether elevated nCFH levels early in disease 
predicts greater likelihood of progression to late AMD. 
In turn elevated nCFH may reflect greater environmental 
exposure to nitrosative stress, and awareness of such 
elevated levels may provide impetus for patients to stop 
smoking cigarettes, modify their diets and perhaps be more 
compliant with consumption of anti-oxidants with a view 
to decreasing their risk of developing late AMD. Assessing 
whether lifestyle modification leads to a decrease in 
plasma levels of nCFH may also be a useful surrogate 
marker for adequacy of such preventative strategies in an 
individual patient, allowing scope for further tailoring of 
treatment. It will also be useful to know whether elevated 
nCFH levels in early AMD predicts a greater likelihood of 
neovascular AMD in view of our findings that nCFH is a 
potent stimulator of inflammatory cytokines such as IL-8 
which is an inducer of angiogenesis [17].
Inhibition of mediators responsible for nitrotyrosine 
post-translational modifications in vivo is a therapeutic 
avenue for AMD implied by our study. One such target 
is peroxynitrite formation, an important player in tyrosine 
nitration pathways. An agent (FeTPPS) that catalytically 
decomposes peroxynitrite to nitrate has been shown to 
prevent tyrosine nitration in an in vivo diabetic retinopathy 
model and an ex vivo human retina model [22]. As such, 
agents that remove excessive peroxynitrite accumulation 
may warrant exploration as a treatment modality in AMD.
MATERIALS AND METHODS
Patients
Patient plasma samples were obtained from a well 
characterised cohort of patients with AMD and controls. 
The AMD cohort consists of a cross sectional group of 30 
patients with either the early stages (n = 17, age 80.6 ± 
5.9, 3 male, 14 female) or late (n = 13, age 83.3 ± 6.1, 5 
male, 8 female) AMD. Controls (n = 30, age 74.8 ± 9.0, 9 
male, 21 female). These patients were well characterised 
with macular photographs graded for AMD according 
to the International Classification and Grading System 
for AMD [23]. Plasma from this cohort has been used 
in previous studies to examine the association of CRP 
levels together with the “at risk” genotype of CFH in the 
prevalence and progression of AMD [24]. Institutional 
ethics was approved by the Royal Victoria Eye and Ear 
Hospital Human Research and Ethics Committee (Project 
#99/3724) and informed consent for patient sampling 
was obtained from all subjects prior to venepuncture. All 
methods were carried out in accordance with approved 
guidelines.
Reagents
Proteins and cell lines
Human CFH, Factor I, C3b, goat anti-C3 antiserum, 
CFH deficient plasma were purchased from CompTech 
(Tyler, Texas). Cytochrome C, essentially fatty acid 
free bovine serum albumin (BSA), anti-mouse alkaline 
phosphatase (ALP) and anti-rabbit ALP were from Sigma 
(St. Louis, MO). Perlecan (HSPG2) was purified from 
conditioned media of human coronary arterial endothelial 
cells by way of anion exchange and immuno-affinity 
chromatography as described previously [25].
A biotinylated goat anti-nitrotyrosine antibody 
was from Abcam (Cambridge, MA). Rabbit polyclonal 
anti-nitrotyrosine antibody was from Sigma or Merck 
Millipore (Billerica, MA). Goat anti-CFH antibody was 
from Millipore. Mouse monoclonal anti-nitrotyrosine 
specific antibody and mouse anti-CFH antibody were 
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from Thermo Scientific (Rockford, IL). MDA-LDL was 
purchased from Cell Biolabs, Inc. (San Diego, CA). Anti-
MDA HRP was from My BioSource, Inc (San Diego, CA). 
Streptavidin-HRP, anti-mouse HRP and anti-goat HRP 
were purchased from Dako (Carpentaria, CA). Isotype 
control murine IgG2 and rabbit polyclonal IgG were 
purchased from BD Pharmingen (San Diego, CA). Rabbit 
anti-goat Alexa 488 or Alexa 594, donkey anti-rabbit 
Alexa 488 or Alexa 594 were from Molecular Probes, Life 
Technologies (New York, NY). ELISA for quantification 
of IL-8 was from BD Pharmingen. The THP-1 monocyte 
cell line was purchased from American Tissue Culture 
Collection (ATCC) (Manassas, VA).
Chemicals
1,1,3,3-Tetramethoxypropane (TMP), Dowex 
50W-X4 resin, acetone, trinitrobenzenesulfonic acid 
(TNBS), acetaldehyde and 2-thiobarbituric acid, 
4-(2-hydroxyethyl)-1 piperazineethanesulfonic acid 
(HEPES), NaNO2 (sodium nitrite), hydrogen peroxide 
(H2O2) (30% w/w), dithiothreitol (DTT), propidium 
iodide, iodoacetamide were purchased from Sigma. Pre-
cast NuPAGE Novex 4–12% gradient SDS-PAGE gels 
were purchased from Life Technologies (Madison, WI). 
Nickel-agarose was purchased from Qiagen (Valencia, 
CA), MDA was from Cayman Chemical (Ann Arbor, MI), 
PolyScreen polyvinyldiethylene fluoride (PVDF) transfer 
membrane and Western blot chemiluminescence reagents 
from GE Healthcare (Bucks, UK). The biotin labelling kit 
and trypsin were from Promega (Madison, WI). EZ-Link 
Sulfo NHS-biotin was from Pierce (Rockford, IL). Super 
frost Plus slides were from Menzel-Glaser (Saarbruckener, 
Germany). All other chemicals were reagent grade.
SDS-PAGE and Western blotting
All samples were resolved on 4–12% gradient SDS-
PAGE gels under non-reducing or reducing conditions 
unless otherwise stated and transferred to PVDF 
membrane. Unless stated otherwise all primary and 
secondary antibody reagents were suspended in blocking 
buffer consisting of Tris-buffered saline – ‘Tween 20’ 
0.1% (TBST) / 5% non-fat dried milk. After blocking for 
1 h at RT the PVDF membrane was probed at 1 h at RT 
(unless stated otherwise) with anti–nitrotyrosine, anti-CFH 
or anti-C3 antibodies. Secondary antibodies were used at 
final dilutions of 1:2000 for anti-mouse HRP and anti-goat 
HRP (RT for 1 h). Resultant bands were visualized using 
chemiluminescence.
Resultant band images were captured using LAS-
4000 Image Capture Unit (GE Healthcare, Little Chalfont, 
UK). Total protein estimations on all samples were 
performed using the BCA Protein Assay.
Synthesis of malondialdehyde sodium salt
50 mmols of 1, 1, 3, 3-tetramethoxypropane (TMP) 
were stirred with 33 ml of the ion-exchange resin Dowex 
50W-X4 in 100 ml of ultra pure water for 30 min at RT. 
The resin was removed by filtration then the filtrate was 
quickly adjusted to pH 8 by adding 5 M NaOH. The 
filtrate was extracted three times with equal volume 
of ethyl acetate and the aqueous layer was dried under 
vacuum at a temperature below 30°C. The residue was 
dissolved in a minimum amount of ultra pure water then 
acetone was carefully added just at the clouding point. The 
crystalline MDA sodium salt was collected by filtration 
and recrystallized twice from water-acetone.
Generation of MAA-BSA
MAA-BSA was generated by incubating 2 mg/
mL of BSA with 100 mmol/L solution of MDA (molar 
mass: 72.0636 g/mol) in the presence of 200 mmol/L 
acetaldehyde in phosphate buffered saline (PBS) at pH 
4.8 for 3.5 h at 37°C in a sealed polypropylene tube in a 
non-oxidizing atmosphere (argon gas). Unmodified BSA 
(2 mg/mL) was used as control. Other controls such as 
MDA- or acetaldehyde-BSA adducts were prepared under 
the same conditions and at similar concentrations of 
acetaldehyde or MDA alone when used in the generation 
of BSA-MAA. Following incubation, unbound MDA and 
acetaldehyde were removed by extensive dialysis against 
3 changes of PBS (2L) for 24 h at 4°C then stored under 
argon in 50 ml polypropylene tubes at 4°C in the dark.
Unmodified BSA 2 mg/ml was used as control. 
Modification of BSA with MAA was assessed by the 
TNBS-test for measuring free amino groups in a protein 
and by measuring the specific MAA fluorescence 
spectrofluorometrically with Perkin Elmer Luminescence 
Spectrometer LS50B (Beaconsfield, England) at excitation 
wavelength 394 nm and emission wavelength 462 nm.
Biotinylation of proteins
Biotin labeling of the proteins was performed using 
EZ-Link SulfoNHS-biotin according to the manufacturer’s 
protocol. The level of biotin incorporation into proteins 
was determined by HABA assay and yielded an average of 
3 molecules of biotin for each molecule of protein.
Tyrosine nitration of CFH in vitro
CFH (1 mg/ml) was incubated in PBS (pH 5.5) at 
37°C with NaNO2 (sodium nitrite 1 nM), cytochrome C 
(25 μM) and H2O2 (3.7 nM). H2O2 was added in 2 separate 
aliquots every 15 min over a 30 min period as previously 
described [26].
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Purification of in vitro generated nitrotyrosine 
CFH
After nitration of CFH, nCFH was purified by 
electro elution. Briefly, nCFH was separated by SDS-
PAGE. The nCFH band identified by Coomassie blue 
staining was excised and subjected to electro elution 
using the D-Tube dialyzer. Electrophoresis was performed 
at 100V over 16 h and electro elution was monitored by 
the loss of blue color in the gel. The purified nCFH was 
collected in the D-Tube dialyzer.
Binding of MDA-LDL to immobilised CFH 
preparations
CFH, nCFH, CFH plus NaNO2 or CFH plus H2O2 
(10 μg/ml) in 0.05 M Carbonate-Bicarbonate (pH 9.6) 
coating buffer (100 μL) was added to Maxisorp microtitre 
wells and incubated overnight at 4°C. After blocking 
with 2% ovalbumin in PBST for 1 h at RT, wells were 
incubated with MDA-LDL (5 μg/mL) in blocking buffer 
for 1 h at RT and specifically bound proteins were detected 
with anti-MDA HRP antibody (1:2000). Optical Density 
(OD) was measured at 370 nm.
Binding of biotinylated BSA adducts to 
immobilized CFH preparations
CFH, nCFH, or purified nCFH (5 μg/ml) in 0.05 M 
Carbonate-Bicarbonate (pH 9.6) coating buffer (100 μL) 
was added to Maxisorp microtitre wells and incubated for 
1 h at 37°C. After blocking with 2% BSA in PBST for 1 h 
at RT, wells were incubated with biotinylated MAA-BSA 
or MAA-BSA or biotinylated BSA (5 μg/mL) as control in 
PBST (0.25% BSA) for 1 h at RT and specifically bound 
biotinylated proteins were detected with Streptavidin HRP 
antibody (1:2000). The OD was measured at 370 nm.
Binding of CFH and nitrotyrosine CFH to 
immobilized perlecan
Perlecan (10 μg/ml) in 0.05 M Carbonate-
Bicarbonate (pH 9.6) coating buffer (100 μL) was added 
to Maxisorp microtitre wells and incubated overnight at 
4°C after blocking with 2% BSA in PBST for 1 h at RT. 
Wells were incubated with CFH (10 μg/ml) or nCFH (10 
μg/ml) or the nitration mixture in blocking buffer for 1 h 
at RT and specifically bound proteins were detected with 
goat anti-CFH (12.5 nM) followed by an anti-goat HRP 
(1:500). OD was measured at 370 nm.
ELISA to detect nCFH
A biotin conjugated anti-nitrotyrosine antibody 
(AbCam) was diluted 1000 fold in 50 mM carbonate 
bicarbonate buffer and coated on a streptavidin plate for 
1 h at RT. After washing 3 times with PBST and blocking 
with 0.5% ovalbumin in PBST for 1 h at RT, nCFH 
standard or 100 fold diluted plasma was added in duplicate 
(100 μl/ well) and incubated for 1 h at 37°C. After washing 
3 times with PBST, nCFH bound to the anti-nitrotyrosine 
antibody was detected with a monoclonal anti-CFH 
antibody. After washing 3 times with PBST, ALP 
conjugated goat anti-mouse antibody was added (1:1500 
dilution at RT for 1 h) and samples read at 405 nm after 
addition of appropriate chromogenic substrate. Negative 
controls were, non nCFH and mouse monoclonal IgG as a 
control for the primary antibody.
An nCFH standard curve was generated for each 
experiment. Purified nCFH was added to CFH deficient 
human plasma. The standard curve concentration range for 
nCFH was between 6.25 ng/ml and 200 ng/ml (Figure 9). 
CFH deficient plasma without the addition of nCFH had 
negligible binding and was used as the negative control.
Determination of coefficient of variation for 
nitrotyrosine CFH ELISA
Intraplate coefficient of variation (CV) was derived 
by the equation: Standard Deviation of optical density 1 
(OD1) and optical density 2 (OD2) divided by the mean 
value of OD1 and OD2, multiplied by 100 to give a 
percentage. OD1 and OD2 are the readings of each point 
on the standard curve done in duplicate. The interplate 
CV was derived by dividing the optical density of the 
100 ng/ml standard curve sample by the optical density 
of the 50 ng/ml standard curve sample to obtain a value 
R for each plate. A total of 7 R values were generated. 
The interplate CV was derived by the standard deviation 
divided by the mean of the R values, multiplied by 100 to 
give a percentage.
CFH preparations binding to C3b
An ELISA method was used to detect binding of 
CFH and nCFH to C3b. C3b (5 μg/ml) in 100 μl of 0.05 
M Carbonate-Bicarbonate (pH 9.6) coating buffer was 
added to Maxisorp microtitre wells and incubated for 1 
h at 37°C. After blocking with 2% BSA, CFH or nCFH 
(8 μg/ml) was added to the wells and incubated for 1 h at 
37°C. Specifically bound CFH and nCFH was detected 
with a goat anti-human CFH polyclonal antibody. Controls 
used were CFH plus H2O2 and CFH plus NaNO2. OD was 
measured at 405 nm.
Cofactor activity of CFH and nCFH for cleavage 
of C3b by Factor I
The cofactor activity of CFH or nCFH or CFH plus 
H2O2 or CFH plus NaNO2 was measured with an assay 
that has been described previously [27, 28].
For C3b cleavage, C3b (10 μg/ml), Factor I (0.72 
μg/ml), CFH (5 μg/ml) or nCFH (5 μg/ml) were incubated 
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at 37°C for 30 min, then the mixture was separated 
under reducing conditions by SDS-PAGE and further 
analyzed by either Western blotting using a goat anti-C3 
antiserum (1:2000) or by Coomassie blue staining. The 
mass spectrometry proteomics data have been deposited 
to the ProteomeXchange Consortium via the PRIDE [30] 
partner repository with the dataset identifier PXD005613 
and 10.6019/PXD005613.
Mass spectrometry of in vitro generated nitrated 
CFH
The nitrated native CFH protein was resolved on 
NuPAGE Novex 4-12% Bis-Tris Gel under non-reducing 
conditions and stained with colloidal Coomassie. The 
protein band was excised from the gel, destained, dried and 
incubated with 100 mM DTT in 25 mM NH4HCO3 for 1 h 
at 25°C. The gel slice was washed with NH4HCO3, dried 
and incubated with 55 mM iodoacetamide (Sigma) in 25 
mM NH4HCO3. The slices were washed and dried before 
digestion of the nitrated CFH protein with 20 ng.μL-1 
trypsin (Promega) in 25 mM NH4HCO3 overnight at 30°C.
Peptides were eluted from the slices with 5% formic 
acid, 50% acetonitrile for 30 min and separated by nano-
LC on an Ultimate 3000 HPLC (Dionex) using a fritless 
nano column (75μ x ~10cm) containing C18 media (5μ, 
200 Å Magic, Michrom). Peptides were eluted using a 
linear gradient of H2O:CH3CN (98:2, 0.1% formic acid) 
to H2O:CH3CN (64:36, 0.1% formic acid) at 250 nL.min-1 
over 60 min. Positive ions were generated by electrospray 
and analyzed in a LTQ FT Ultra (Thermo Electron) 
mass spectrometer operated in data dependent MS/MS 
acquisition mode.
Mass spectral data were searched using Mascot 
(V2.3, Matrix Science) against the non-redundant 
database from NCBI. Search parameters were: precursor 
tolerance 6 ppm and product ion tolerances ± 0.5 Da. Cys-
carboxyamidomethyl was selected as a fixed modification 
and Met-O, Trp-O, Tyr-NO2 and Pyro-Glu/Gln were 
selected as variable modifications with full tryptic 
cleavage of up to 2 missed cleavages.
Quantification of the nitrated peptides was 
performed by calculating the area under the extracted ion 
chromatogram for the precursor ions (+2 and +3) using 
the Xcalibur™ Software (Thermo Scientific, v2.2). The 
mass spectrometry proteomics data have been deposited 
to the ProteomeXchange Consortium via the PRIDE [29] 
partner repository with the dataset identifier PXD005613 
and 10.6019/PXD005613. 
Human adult eyes
Adult human eyes with age-related macular 
degeneration (n = 5) (age range 69 to 93 years) were 
obtained, with consent, from the Lions NSW Eye Bank, 
and with ethics approval from the University of NSW and 
University of Sydney Human Research Ethics Committees. 
All procedures were in accordance with the Declaration of 
Helsinki. The delay from death to fixation was less than 16 
h for all eyes. Following removal of the anterior segment 
(iris, lens or intraocular lens) and vitreous, the eyecups 
were rinsed in 0.1M PBS and the retina/choroid examined 
using a dissecting stereomicroscope and imaged using a 
digital camera (Leica DFC480) and Photoshop software. 
Images were used to further classify the eyes where 
appropriate, using the Age Related Eye Disease Study 
(AREDS) grading system to assess stages of AMD [30], 
together with any history of AMD. Human eyes were fixed 
in 2% paraformaldehyde PBS (pH 7.4) for at least 24 h. 
Eyes were then dissected and the central region including 
macular and optic disc, and peripheral nasal and temporal 
regions paraffin embedded and sections were at 8 μm and 
collected on Super-Frost Plus slides. Histopathology was 
assessed in sections stained with Mayer’s haematoxylin 
and eosin (H&E) or Periodic Acid Schiff (PAS) using 
standard protocols. Stained sections were dehydrated 
through alcohols and xylenes, then coverslipped in DePeX.
For two postmortem eyes (aged 87 and 93 years), 
the unfixed retina and choroid/RPE, were gently separated 
and removed from the eyecup, snap frozen in eppendorf 
tubes in liquid nitrogen and stored at -80°C for use in 
protein assays (see above).
Immunohistochemistry
Sections were dewaxed and rehydrated through 
alcohols to water. For antigen retrieval, sections were 
incubated in 0.01M sodium citrate buffer (pH 6) at 95°C 
for 10 min, cooled to 40°C, and washed with Tris-buffered 
saline (pH 7.4) and 0.1% Tween-20 (TBST). Sections were 
incubated at RT in 5% BSA in TBST for 30 min followed 
by incubation overnight at 4°C in primary antibodies 
(goat anti-CFH 1:1000, rabbit anti-nitrotyrosine 1:500). 
Negative controls were treated identically, using non-
specific Ig (rabbit or goat Ig) at appropriate concentrations.
After incubation, sections were washed in TBST 
for 10 min, then incubated with either donkey anti-
rabbit Alexa 488 (1:1000) and rabbit anti-goat Alexa 594 
(1:1000) for 2 h at RT, and rinsed again in TBS. Cell nuclei 
were counter-stained with bisbenzimide H33258 (Sigma) 
(0.1 μg/ml) for 5 min, followed by rinsing in TBS. After 
a final rinse in TBS, sections were mounted in glycerol, 
coverslipped and sealed with nail varnish, and dried before 
microscopy.
Confocal microscopy
Immunolabelled sections were examined with a 
Zeiss LSM-5 PASCAL laser scanning confocal microscope 
system (Carl Zeiss, Germany). Images were collected as 
single scans using LSM 5 Pascal Version 3.2 SP2 software. 
Multichannel excitation bleed through was minimized 
by using fluorochromes with different peak excitations 
(488 nm and 594 nm respectively). Emission bleed 
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through was minimized by Multi-tracking, where signal 
crosstalk between neighbouring channels was corrected 
by performing sequential image capture. The combined 
images were acquired with an acquisition process using 
a single excitation /single detection channel. Images were 
also collected using Z-stacks as appropriate. Images were 
exported to Adobe Photoshop CS5 for further analysis. 
Laser excitation levels were constant for all imaging.
Interleukin-8 secretion by THP-1 human 
monocytic cell line stimulated with MAA-BSA
Human THP-1 monocytic cells were cultured in 
RPMI-1640 medium supplemented with 10% FCS. Before 
stimulation, cells were starved in serum-free RPMI-1640 
then incubated with the stimulation medium at a density 
of 5 x 105 cells/well for 18 h. The stimulation medium 
contained MAA-BSA (50 μg/ml) and/or combinations of 
CFH, nitrated CFH, H2O2, cytochrome C or NaNO2 at 100 
μg/ml, incubated for 30 min at RT before plating. Cells 
were removed by centrifugation (1000 rpm, 10 min) and 
supernatants were assayed for IL-8 by ELISA according 
to the manufacturer’s (Beckton Dickinson) instructions.
Isolation of whole protein from an AMD 
affected retina
Total protein was extracted from the liquid 
nitrogen frozen human retina tissue using the lysis buffer 
containing 50 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 1 
mM EDTA, 0.1% Triton X-100, and 0.1% (wt/vol) SDS 
with a protease inhibitor cocktail (Sigma). In brief, 
retinal tissue in 100 μl of lysis buffer was homogenized 
on ice for 5 min. The supernatant was collected after 
centrifugation at 5000 g for 10 min. The protein was 
quantitated using the BCA reagent, and aliquots were 
stored in -80°C.
Generation of an anti-nitrotyrosine monoclonal 
antibody that has restricted specificity to purify 
nCFH from AMD retina
Hybridoma cells producing a monoclonal antibody 
(designated C166) was derived to the nitrated peptide 
AC-KEKKCS(YNO2)TED-NH2 sequence from 
Apolipoprotein H a protein in the same complement 
control superfamily as CFH using their proprietary 
technology (Abmart, Berkeley Heights, NJ). For 
production of purified monoclonal antibodies, hybridoma 
cells were cultured in culture media DMEM/F12 
containing 5% FBS. When cell density reached 1×106/
ml, the supernatant was collected after 12 h incubation 
in serum free medium. The C166 monoclonal antibody in 
the supernatant was purified using the Montage Antibody 
Purification Kit (Merck Millipore). The concentration of 
the purified C166 anti-nCFH monoclonal antibody was 
measured by Nano-drop 2000c (Thermo Fisher).
Affinity purification of nCFH from the retina of 
a deceased AMD patient
The AminoLink® Plus Immobilization Kit (Thermo 
Scientific) was used to couple the purified anti-nCFH 
monoclonal antibody. The coupling steps were followed 
as outlined in the manufacturer’s instructions. 1 mg 
of monoclonal C166 antibody in coupling buffer was 
added to the AminoLink plus Column and incubated 
for 4 h at RT. After washing 4 times with the coupling 
buffer, the column was incubated in coupling buffer 
plus sodium cyanoborohydride solution for another 4 h 
at RT. After extensive washing of the column, unbound 
sites on the column were blocked by the quenching 
buffer plus the sodium cyanoborohydride solution. After 
30 min of incubation and washing 4 times, the column 
was used to extract affinity purified nCFH from the 
whole retinal protein extract. The samples containing 
the retinal protein extract were diluted in PBS buffer and 
applied to the affinity column. After 1 h incubation at 
RT, the column was washed with PBS buffer. The bound 
protein was eluted with elution buffer (0.1M glycine-HCl 
at pH 2.5-3.0) and the flow through was collected in a 
tube containing neutralization buffer (1M Tris-HCl at pH 
8.5-9.0).
Statistical analysis
Results were analysed by the Mann-Whitney test. A 
p value of < 0.05 is taken to signify statistical significance.
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